Characteristics of the cohort
| Demographic features | |
| Number | 324 |
| Age (years) | 42.7±10.8 |
| Gender (female) | 242 (74.7%) |
| Clinical characteristics | |
| Disease course: RR | 303 (93.5%) |
| SP | 15 (4.6%) |
| PP | 6 (1.9%) |
| Disease duration (years) | 11.9±8.5 |
| EDSS Score at the time of vaccination | 2.1±1.5 |
| DMTs at the time of vaccination | |
| Glatiramer acetate | 21 (6.5%) |
| Interferons | 52 (16.0%) |
| Dimethyl fumarate | 84 (25.9%) |
| Teriflunomide | 20 (6.2%) |
| Fingolimod | 31 (9.6%) |
| Natalizumab | 37 (11.4%) |
| Cladribine | 9 (2.8%) |
| Ocrelizumab | 31 (9.6%) |
| Siponimod | 1 (0.3%) |
| Alemtuzumab | 5 (1.5%) |
| Rituximab | 5 (1.5%) |
| Azathioprine | 1 (0.3%) |
| Methotrexate | 1 (0.3%) |
| No therapy | 26 (8.0%) |
Continuous variables are reported as mean±SD. Categorical variables are reported as number (percentage).
DMTs, disease-modifying treatments; EDSS, Expanded Disability Status Scale; PP, primary progressive; RR, relapsing remitting; SP, secondary progressive.